David A. Siegel Crinetics Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 67,300 shares of CRNX stock, worth $2.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,300

Previous 6,300 968.25%

Holding current value

$2.88 Million

Previous $211,000 817.06%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$25.56 - $33.76 $1.56 Million - $2.06 Million	61,000 Added 968.25%	67,300 $1.94 Million
Q1 2025 May 15, 2025	SELL	$32.3 - $53.15 $58,139 - $95,670	-1,800 Reduced 22.22%	6,300 $211,000
Q4 2024 Feb 14, 2025	SELL	$50.66 - $60.69 $724,438 - $867,867	-14,300 Reduced 63.84%	8,100 $414,000
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $490,896 - $615,776	-11,200 Reduced 33.33%	22,400 $1.14 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $75,816 - $93,438	1,800 Added 5.66%	33,600 $1.5 Million
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $243,320 - $327,670	-7,000 Reduced 18.04%	31,800 $1.49 Million
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $1.18 Million - $1.71 Million	-46,100 Reduced 54.3%	38,800 $1.38 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $359,325 - $688,275	22,500 Added 36.06%	84,900 $2.52 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $33,033 - $49,560	2,100 Added 3.48%	62,400 $1.12 Million
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $598,621 - $825,010	-39,100 Reduced 39.34%	60,300 $968,000
Q4 2022 Feb 14, 2023	SELL	$15.49 - $19.05 $450,759 - $554,355	-29,100 Reduced 22.65%	99,400 $1.82 Million
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $23,543 - $29,081	-1,300 Reduced 1.0%	128,500 $2.52 Million
Q2 2022 Aug 15, 2022	SELL	$16.49 - $27.64 $189,634 - $317,860	-11,500 Reduced 8.14%	129,800 $2.42 Million
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $190,364 - $314,241	-11,100 Reduced 7.28%	141,300 $3.1 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $243,810 - $357,966	12,600 Added 9.01%	152,400 $4.33 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $925,024 - $1.38 Million	54,800 Added 64.47%	139,800 $2.94 Million
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $806,130 - $1.07 Million	50,700 Added 147.81%	85,000 $1.6 Million
Q1 2021 May 17, 2021	BUY	$13.3 - $17.55 $155,610 - $205,335	11,700 Added 51.77%	34,300 $524,000
Q4 2020 Feb 16, 2021	BUY	$12.08 - $17.46 $124,424 - $179,838	10,300 Added 83.74%	22,600 $319,000
Q3 2020 Nov 16, 2020	BUY	$13.62 - $17.66 $6,810 - $8,830	500 Added 4.24%	12,300 $193,000
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $153,872 - $274,114	11,800 New	11,800 $207,000

Others Institutions Holding CRNX

# of Institutions

238

Shares Held

90.2M

Call Options Held

59.7K

Put Options Held

14.8K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.3B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account